Company: Teva Pharmaceutical Industries
Drug Type: Small Molecule
Mechanism Type: Glutamate Excitotoxicity Blocker
Mechanism: Talampanel is a selective non-competitive antagonist of AMPA receptors, a type of glutamate receptor. Talampanel was tested as a drug to reduce neuronal death due to glutamate excitotoxicity.
U.S. Status for ALS: Discontinued
 Talampanel for Amyotrophic Lateral Sclerosis (ALS). ClinicalTrials.gov, 20 Oct 2011. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT00696332.
 A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Pascuzzi, RM et al. Amyotroph Lateral Scler. 2010 May 3;11(3):266-71.
Last updated March 11th, 2019